Inclusion Criteria:  Female gender ≥ 50 years of age DXA T-score of > -2.5 standard deviations, but ≤ -1 (osteopenic range) Steady state body weight 1 month before study commencement date No contraindications for intake of the interventional product, including a prior diagnosis of fish allergy. Familiar with the Norwegian language, both in writing and orally  Exclusion Criteria:  A diagnosis of osteoporosis (BMD T-score ≤ -2.5 SD as diagnosed by DXA), or any previously diagnosed fragility fractures.  Use of drugs known to affect bone metabolism, including:  Glucocorticoids Thyroid hormones Hormone replacement therapy Long-term heparin therapy Anti-convulsive drugs Long-term proton pump inhibitor treatment Lithium Anti-osteoporotic drugs Cancer therapy Selective estrogen receptor modulators. Any disease or medical condition known to affect bone tissue, including neoplasia with or without metastasis, Paget's disease of bone, Osteomalacia, or any other disease deemed relevant by the PI. Gastrointestinal diseases or disturbances potentially affecting absorption of nutrients, including Crohn's disease and Celiac disease. Hypersensitivity to ingredients in the interventional product, including fish allergy. Not willing to participate in the study. Other reasons that the PI deems it necessary to exclude the subject.